Michael Wolgin

Prof. Dr. Michael Wolgin

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Archives of Oral Biology
Verified
Journal Article
Closed access
VHVivian Hirsch
Vivian Hirsch
MWMichael Wolgin
Michael Wolgin
AMAleksandr V. Mitronin
Aleksandr V. Mitronin
AKAndrej Kielbassa
Andrej Kielbassa

25 March 2018 in European Journal of Dental Education
Verified
Journal Article
Closed access
PDF file
MWMichael Wolgin
Michael Wolgin
SGS. Grabowski
S. Grabowski
SES. Elhadad
S. Elhadad
WFW. Frank
W. Frank
AKAndrej Kielbassa
Andrej Kielbassa

1 April 2010
Verified
Journal Article
Closed access
PTPeter Tschoppe
Peter Tschoppe
MWMichael Wolgin
Michael Wolgin
NPNicole Pischon
Nicole Pischon
AKAndrej Kielbassa
Andrej Kielbassa

1 November 2015 in Journal of Dental Education
Verified
Journal Article
Closed access
PDF file
MWMichael Wolgin
Michael Wolgin
PWPaul Wiedemann
Paul Wiedemann
WFWilhelm Frank
Wilhelm Frank
KWKarl‐Thomas Wrbas
Karl‐Thomas Wrbas
AKAndrej Kielbassa
Andrej Kielbassa

14 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MWMichael Wolgin
Michael Wolgin
MZMagdalena Zobernig
Magdalena Zobernig
VDValentyn Dvornyk
Valentyn Dvornyk
Ralf BraunRalf Braun
Ralf Braun
AKAndrej Kielbassa
Andrej Kielbassa
Extracellular plaques composed of the hydrophobic peptide amyloid-β and intraneuronal accumulation of the hyperphosphorylated protein tau (p-tau) are pathological hallmarks found in the brains of most people affected by Alzheimer’s disease (AD). In Parkinson’s disease (PD), Lewy bodies, i.e., intraneuronal protein deposits comprising the protein α-synuclein, are a typical disease feature. As these hallmarks located in the brain are hardly traceable, reliable biomarkers from easily accessible body fluids are key for accurate diagnosis. The aim of the present work was to review the available literature regarding potential biomarkers of AD and PD in the saliva. The databases PubMed, Google Scholar, LILACS, LIVIVO, VHL regional portal, Cochrane Library, eLIBRARY, and IOS Press were consulted for the literature search. Screening of titles and abstracts followed the PRISMA guidelines, while data extraction and the assessment of full texts were carried out in accordance with the Newcastle–Ottawa Scale assessment. The review shows significant increases in levels of the amyloid-β Aβ1-42 and elevated p-tau to total tau (t-tau) ratios in salivary samples of AD patients, in comparison with healthy controls. In PD patients, levels of α-synuclein in salivary samples significantly decreased compared to healthy controls, whereas oligomeric α-synuclein and the ratio of oligomeric α-synuclein to total α-synuclein markedly increased. Salivary biomarkers represent a promising diagnostic tool for neurodegenerative diseases. Further high-quality case–control studies are needed to substantiate their accuracy.

7 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
LWLouisa M. Wendorff-Tobolla
Louisa M. Wendorff-Tobolla
MWMichael Wolgin
Michael Wolgin
GWGernot Wagner
Gernot Wagner
IKIrma Klerings
Irma Klerings
ADAnna Dvornyk
Anna Dvornyk
AKAndrej Kielbassa
Andrej Kielbassa
This meta-analysis intended to assess evidence on the efficacy of locally delivered curcumin/turmeric as an adjunctive to scaling and root planing (SRP), on clinical attachment level (CAL) and probing pocket depth (PPD), compared to SRP alone or in combination with chlorhexidine (CHX). RCTs were identified from PubMed, Cochrane Library, BASE, LIVIVO, Dentistry Oral Sciences Source, MEDLINE Complete, Scopus, ClinicalTrials.gov, and eLibrary, until August 2022. The risk of bias (RoB) was assessed with the Cochrane Risk of Bias tool 2.0. A random-effects meta-analysis was performed by pooling mean differences with 95% confidence intervals. Out of 827 references yielded by the search, 23 trials meeting the eligibility criteria were included. The meta-analysis revealed that SRP and curcumin/turmeric application were statistically significantly different compared to SRP alone for CAL (−0.33 mm; p = 0.03; 95% CI −0.54 to −0.11; I2 = 62.3%), and for PPD (−0.47 mm; p = 0.024; 95% CI −0.88 to −0.06; I2 = 95.5%); however, this difference was considered clinically meaningless. No significant differences were obtained between patients treated with SRP and CHX, compared to SRP and curcumin/turmeric. The RoB assessment revealed numerous inaccuracies, thus raising concerns about previous overestimates of potential treatment effects.